This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Mar 11, 2026
•
9 min read
🧬 Breakout Ventures raises $114M third fund - supporting AI-focused early-stage biotechs, CSL breaks ground on $1.5B plasma medicine plant expansion in Illinois - creating 300 jobs by 2031, GSK's Wellcovorin (leucovorin) wins FDA approval for cerebral folate deficiency targeting folate receptor 1
Mar 10, 2026
🧬 Novo Nordisk + Hims & Hers partner to sell GLP-1 drugs Ozempic and Wegovy, ending lawsuit dispute, Alfasigma + GSK strike $690M deal for linerixibat itching treatment awaiting FDA approval, Regeneron Pharmaceuticals reports positive Ph3 data for olatorepatide (olatorepatide) targeting GLP-1/GIP receptors for obesity treatment, Relmada Therapeutics raises $160M private placement, advancing oncology and CNS therapies, FDA's Prasad departure boosts rare disease biotechs uniQure, Replimune, Disc Medicine stock prices premarket Monday
Mar 9, 2026
8 min read
🧬 Servier acquires Day One Biopharmaceuticals for $2.5B to expand childhood brain tumor portfolio with Ojemda, Sanofi + EMS strike deal to sell generics manufacturer Medley for above $500M, Pfizer's Xianyida (ecnoglutide) wins China approval for obesity treatment targeting GLP-1 receptor following Ph3 results
Mar 6, 2026
🧬 Portal Innovations to open 30,000-square-foot biotech incubator in Salt Lake City by 2027, Zealand Pharma's petrelintide shows placebo-like tolerability with 10.7% weight loss in Ph2 obesity trial, BioDuro + Cenra API Solutions form Taiwan joint venture for end-to-end API manufacturing services
Mar 5, 2026
🧬 Roche invests $484M in South Korea to establish global clinical trial ecosystem, Ireland maintains biopharma investment appeal despite US tariff uncertainty and geopolitical trade tensions, UK invests $64M in NHS equipment to expand clinical trial access to underserved communities, ARPA-H launches $158M program for first-ever lymphatic system drug development, Blackstone Life Sciences + Teva Pharmaceutical partner on gut disease drug duvakitug with $400M commitment, Nvidia, Droplet Biosciences partner on AI-accelerated genomic analysis for lymph-based liquid biopsy testing
Mar 4, 2026
20 min read
🧬 Novo Nordisk commits $506M to upgrade Irish facility for oral Wegovy production ahead of European approval, Alveus Therapeutics raises $37M Series A extension for obesity drug development, Atrium Therapeutics spins out of Novartis-acquired Avidity with $270M to develop RNA medicines for rare heart diseases, Roche's fenebrutinib (BTK inhibitor) hits Ph3 goals in relapsing multiple sclerosis despite safety concerns, Sanofi + Sino Biopharmaceutical license JAK/ROCK inhibitor rovadicitinib globally, $135M upfront +$1.53B total, Earendil Labs + WuXi XDC partner on next-gen ADC linker technology + $885M total deal, Moderna's mCombriax combination flu and COVID-19 vaccine wins European drug regulators' positive recommendation for ages 50+
Feb 27, 2026
🧬 Generate Biomedicines raises $400M IPO - AI drug discovery specialist developing asthma treatments, Asahi Kasei acquires Germany's Aicuris for $920M to boost viral infection R&D portfolio, Eli Lilly's orforglipron (GLP-1) outperforms Novo's Rybelsus in Ph3 diabetes trial on weight loss and blood sugar
Feb 26, 2026
🧬 Novartis selects Denton, Texas for fifth US radiopharmaceutical facility - generating $280M investment and 175 jobs, BreezeBio raises $60M Series B - genetic medicines using specialized nanoparticles, Novo Nordisk + Vivtex collaborate on oral biologics for obesity, up to $2.1B in milestones, Gilead's bictegravir/lenacapivir combo shows Ph2/3 non-inferiority results for human immunodeficiency virus treatment, GSK to buy 35Pharma for $950M - gaining pulmonary hypertension hopeful HS235, Pfizer + Beam Therapeutics global license for liver-targeted gene editing candidate - $1.05B milestone potential
Feb 25, 2026
🧬 Western biopharma licensing deals with Chinese companies surge 230% in upfront values - reaching $172M average, Pfizer + Sciwind Biosciences partner on Chinese GLP-1 ecnoglutide commercialization - up to $495M deal, Sanofi and Regeneron's Dupixent (dupilumab) wins FDA approval for allergic fungal rhinosinusitis following Ph3 success
Feb 24, 2026
10 min read
🧬 Gilead to acquire CAR T partner Arcellx for $7.8B ahead of potential anito-cel approval, Generate:Biomedicines plans $425M IPO to bankroll antibody's phase 3 asthma trials, Harbour BioMed + Solstice Oncology license anti-CTLA-4 antibody HBM4003 - $105M upfront + $1.2B total, Fortress Biotech sells FDA priority review voucher for $205M following Zycubo approval, Bora Pharmaceuticals + GSK renew five-year manufacturing agreement covering 335 products worth $250M, FDA publishes draft guidance for personalized genetic medicines targeting rare diseases through Plausible Mechanism Pathway
Feb 23, 2026
🧬 Candel Therapeutics $100M royalty deal to fund prostate cancer drug launch, Vanda Pharmaceuticals wins FDA approval for Bysanti (milsaperidone) targeting bipolar I disorder and schizophrenia, Virion Therapeutics reports sustained anti-hepatitis B virus immunity from single VRON-0200 dose in Ph1 study
Feb 20, 2026
🧬 Insmed CEO defends "audacious" $1B Brinsupri 2026 sales projection after strong Q4 launch performance, Altesa BioSciences raises $75M Series B - advancing lung drug vapendavir, Merck & Co.'s Enflonsia (clesrovimab) shows positive Ph3 results for second-season respiratory syncytial virus prevention
